These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 15505109

  • 1. Cellular basis for therapeutic choices in heart failure.
    Opie LH.
    Circulation; 2004 Oct 26; 110(17):2559-61. PubMed ID: 15505109
    [No Abstract] [Full Text] [Related]

  • 2. Conclusions on the management of heart failure.
    Swedberg K.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 26; 5 Suppl 1():S34-6. PubMed ID: 15526241
    [Abstract] [Full Text] [Related]

  • 3. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 4. Reassessing guidelines for heart failure.
    Drexler H, Wollert KC.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 16; 5 Suppl 1():S28-33. PubMed ID: 15526240
    [Abstract] [Full Text] [Related]

  • 5. [Is it always necessary to use triple combination in the treatment of patients with chronic cardiac failure? Choice of the third neurohormonal blocker].
    Belenkov IuN, Mareev VIu, Skvortsov AA.
    Ter Arkh; 2008 Sep 16; 80(9):5-12. PubMed ID: 19555028
    [No Abstract] [Full Text] [Related]

  • 6. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 16; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 7. [Antiarrhythmic drug therapy in patients with heart failure].
    Nakamura K, Nishii N, Ohe T.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():369-74. PubMed ID: 17571408
    [No Abstract] [Full Text] [Related]

  • 8. [Anti-atherosclerotic effect].
    Takai S, Miyazaki M.
    Nihon Rinsho; 2006 Jul 28; 64 Suppl 5():518-23. PubMed ID: 16895221
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacologic therapies across the continuum of left ventricular dysfunction.
    Abraham WT, Greenberg BH, Yancy CW.
    Am J Cardiol; 2008 Sep 08; 102(5A):21G-28G. PubMed ID: 18722188
    [Abstract] [Full Text] [Related]

  • 10. Strategies to attenuate pathological remodeling in heart failure.
    Eapen Z, Rogers JG.
    Curr Opin Cardiol; 2009 May 08; 24(3):223-9. PubMed ID: 19318933
    [Abstract] [Full Text] [Related]

  • 11. Aldosterone blockade in heart failure.
    Struthers AD.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 08; 5 Suppl 1():S23-7. PubMed ID: 15526239
    [Abstract] [Full Text] [Related]

  • 12. Aldosterone receptor antagonism and heart failure: insights from an outpatient clinic.
    Mariotti R, Borelli G, Coceani M, Zingaro S, Barison A, Morelli I, Rondinini L.
    J Clin Pharm Ther; 2008 Aug 08; 33(4):349-56. PubMed ID: 18613852
    [Abstract] [Full Text] [Related]

  • 13. The HF epidemic: the need for new treatment strategies.
    Carson PE.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 08; 1(2 Suppl):S32-4. PubMed ID: 17199218
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 08; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 15. [New findings with RAS inhibitors in diabetic nephropathy].
    Ito S.
    Nihon Jinzo Gakkai Shi; 2007 Oct 08; 49(5):485-90. PubMed ID: 17695809
    [No Abstract] [Full Text] [Related]

  • 16. [Adrenergic activation in heart failure: blockade or rebalance?].
    Emdin M, Vergaro G, Giannoni A, Passino C.
    G Ital Cardiol (Rome); 2010 Mar 08; 11(3):229-32. PubMed ID: 20550063
    [No Abstract] [Full Text] [Related]

  • 17. [Heart failure associated with ischemic cardiomyopathy].
    Ogawa T.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():413-20. PubMed ID: 17571414
    [No Abstract] [Full Text] [Related]

  • 18. Filling the gap between guidelines and clinical practice in heart failure treatment: still a far cry from reality.
    Remme WJ.
    Eur J Heart Fail; 2007 Dec 28; 9(12):1143-5. PubMed ID: 17936067
    [No Abstract] [Full Text] [Related]

  • 19. [Effect of combination therapy with angiotensin II type I receptor and aldosterone receptor blockers in heart failure].
    Aoyama N.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():145-9. PubMed ID: 17569312
    [No Abstract] [Full Text] [Related]

  • 20. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U, Wollert KC, Drexler H.
    Cardiovasc Res; 2009 Feb 15; 81(3):519-27. PubMed ID: 19019834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.